Abstract |
Scientific advances in cardiovascular research during the last decades have afforded effective pharmacological treatment to those surviving their first acute myocardial infarction. This secondary prevention treatment, based upon the combined administration of statins, aspirin, beta-blockers and renin- angiotensin blockers, might avert great part of the relapses contributing substantially to the overall incidence of acute coronary syndromes in the general population. However, a treatment gap separates evidence-based recommendations from their daily clinical application, a condition frequently explored even in the Italian medical setting. However, a general overview of the problem is missing insofar, a contribution that might eventually help to improve the status of secondary coronary prevention in our national environment.
|
Authors | Roberto Pedrinelli, Marco Ciccone, Salvatore Novo, Alberico L Catapano |
Journal | Giornale italiano di cardiologia (2006)
(G Ital Cardiol (Rome))
Vol. 13
Issue 11
Pg. 734-40
(Nov 2012)
ISSN: 1827-6806 [Print] Italy |
Vernacular Title | La prevenzione farmacologica delle recidive coronariche nella pratica clinica italiana: una revisione della letteratura. |
PMID | 23096582
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Platelet Aggregation Inhibitors
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Drug Therapy, Combination
- Evidence-Based Medicine
- Follow-Up Studies
- Guideline Adherence
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Italy
- Myocardial Infarction
(drug therapy, prevention & control)
- Patient Discharge
- Platelet Aggregation Inhibitors
(therapeutic use)
- Practice Guidelines as Topic
- Prognosis
- Quality of Life
- Risk Assessment
- Risk Factors
- Secondary Prevention
- Treatment Outcome
|